Barbara M Szczerba1, Paulina Kaplonek2, Nina Wolska2, Anna Podsiadlowska2, Paulina D Rybakowska3, Paromita Dey4, Astrid Rasmussen2, Kiely Grundahl2, Kimberly S Hefner5, Donald U Stone6, Stephen Young7, David M Lewis8, Lida Radfar8, R Hal Scofield9, Kathy L Sivils2, Harini Bagavant3, Umesh S Deshmukh3. 1. Division of Nephrology, University of Virginia, Charlottesville, Virginia, USA University of Basel, Basel, Switzerland. 2. Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA. 3. Division of Nephrology, University of Virginia, Charlottesville, Virginia, USA Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA. 4. Division of Nephrology, University of Virginia, Charlottesville, Virginia, USA. 5. Hefner Eye Care and Optical Center, Oklahoma City, Oklahoma, USA. 6. Department of Ophthalmology, Dean McGee Eye Institute, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA. 7. University of Oklahoma College of Dentistry, Oklahoma City, Oklahoma, USA. 8. Department of Oral Diagnosis and Radiology, University of Oklahoma College of Dentistry, Oklahoma City, Oklahoma, USA. 9. Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA Department of Veterans, Affairs Medical Center, Oklahoma City, Oklahoma, USA.
Abstract
OBJECTIVES: Autoantibodies reactive with Ro52 are often found in sera of patients with Sjögren's syndrome (SS). This study was undertaken to investigate the role of Ro52-induced immune responses in pathogenesis of SS. METHODS: New Zealand Mixed (NZM) 2758 mice were immunised with Ro52 in alum adjuvant. Control mice were immunised either with maltose-binding protein or injected with alum alone. Mice were monitored for anti-Ro52 antibody, sialoadenitis and pilocarpine-induced salivation. Antibody binding to salivary gland (SG) cells was analysed in vivo and in vitro by immunofluorescence. Sera from immunised mice were passively transferred into untreated or alum injected NZM2758 mice. RESULTS: By day 30 post-immunisation, Ro52 immunised mice generated immunoprecipitating anti-Ro52 antibodies and they had the maximum drop in saliva production. Both Ro52 immunised and control mice showed evidence of mild sialoadenitis. However, only Ro52 immunised mice had antibody deposition in their SG. Passive transfer of Ro52-immune sera induced SG dysfunction in recipient mice, only if the recipients were primed with alum. In vitro, antibodies from Ro52-immune sera were internalised by a SG cell line and this uptake was inhibited by cytochalasin D treatment. CONCLUSIONS: Our data show for the first time that antibodies induced by Ro52 are capable of inducing SG dysfunction, and that this phenomenon is dependent on the activation of innate immunity. The mouse model described in this study implies that autoantibody deposition in the SG might be an important step in the induction of xerostomia and pathogenesis of SS. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
OBJECTIVES: Autoantibodies reactive with Ro52 are often found in sera of patients with Sjögren's syndrome (SS). This study was undertaken to investigate the role of Ro52-induced immune responses in pathogenesis of SS. METHODS: New Zealand Mixed (NZM) 2758 mice were immunised with Ro52 in alum adjuvant. Control mice were immunised either with maltose-binding protein or injected with alum alone. Mice were monitored for anti-Ro52 antibody, sialoadenitis and pilocarpine-induced salivation. Antibody binding to salivary gland (SG) cells was analysed in vivo and in vitro by immunofluorescence. Sera from immunised mice were passively transferred into untreated or alum injected NZM2758 mice. RESULTS: By day 30 post-immunisation, Ro52 immunised mice generated immunoprecipitating anti-Ro52 antibodies and they had the maximum drop in saliva production. Both Ro52 immunised and control mice showed evidence of mild sialoadenitis. However, only Ro52 immunised mice had antibody deposition in their SG. Passive transfer of Ro52-immune sera induced SG dysfunction in recipient mice, only if the recipients were primed with alum. In vitro, antibodies from Ro52-immune sera were internalised by a SG cell line and this uptake was inhibited by cytochalasin D treatment. CONCLUSIONS: Our data show for the first time that antibodies induced by Ro52 are capable of inducing SG dysfunction, and that this phenomenon is dependent on the activation of innate immunity. The mouse model described in this study implies that autoantibody deposition in the SG might be an important step in the induction of xerostomia and pathogenesis of SS. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Authors: Linn Strandberg; Aurelie Ambrosi; Alexander Espinosa; Lars Ottosson; Maija-Leena Eloranta; Wei Zhou; Ase Elfving; Edward Greenfield; Vijay K Kuchroo; Marie Wahren-Herlenius Journal: J Clin Immunol Date: 2008-05 Impact factor: 8.317
Authors: Troy E Daniels; Darren Cox; Caroline H Shiboski; Morten Schiødt; Ava Wu; Hector Lanfranchi; Hisanori Umehara; Yan Zhao; Stephen Challacombe; Mi Y Lam; Yvonne De Souza; Julie Schiødt; Helena Holm; Patricia A M Bisio; Mariana S Gandolfo; Toshioki Sawaki; Mengtao Li; Wen Zhang; Beni Varghese-Jacob; Per Ibsen; Alicia Keszler; Nozomu Kurose; Takayuki Nojima; Edward Odell; Lindsey A Criswell; Richard Jordan; John S Greenspan Journal: Arthritis Rheum Date: 2011-07
Authors: P Ghillani; C André; C Toly; A M Rouquette; D Bengoufa; P Nicaise; C Goulvestre; A Gleizes; M A Dragon-Durey; M A Alyanakian; P Chretien; S Chollet-Martin; L Musset; B Weill; C Johanet Journal: Autoimmun Rev Date: 2011-04-05 Impact factor: 9.754
Authors: Claudia M Trujillo-Vargas; Laura Schaefer; Jehan Alam; Stephen C Pflugfelder; Robert A Britton; Cintia S de Paiva Journal: Ocul Surf Date: 2019-10-20 Impact factor: 5.033
Authors: Nina Wolska; Paulina Rybakowska; Astrid Rasmussen; Michael Brown; Courtney Montgomery; Arkadiusz Klopocki; Kiely Grundahl; Robert H Scofield; Lida Radfar; Donald U Stone; Juan M Anaya; John A Ice; Christopher J Lessard; David M Lewis; Nelson L Rhodus; Rajaram Gopalakrishnan; Andrew J W Huang; Pamela J Hughes; Michael D Rohrer; Michael H Weisman; Swamy Venuturupalli; Joel M Guthridge; Judith A James; Kathy L Sivils; Harini Bagavant; Umesh S Deshmukh Journal: Arthritis Rheumatol Date: 2016-03 Impact factor: 10.995